This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): DARA, RE-021, RE021, RE 021, PS433540
Description: PS433540 is a Dual-Acting angiotensin and endothelin Receptor Antagonist (DARA). The compound works by selectively blocking the action of two vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. PS433540 is highlyselective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. Preclinical data suggests that compared to either agent alone, simultaneously blocking theactions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.
Deal Structure: In March 2006, Pharmacopeia entered into an exclusive licensing agreement with Bristol-Myers Squibb (BMS) providing Pharmacopeia worldwide development and commercialization rights to certain compounds discovered by BMS that possess dual angiotensin (AT1) and endothelin (ETA) receptor antagonist (DARA) activity. Under the agreement, Pharmacopeia acquired exclusive rights to lead and backup DARA development candidates under the BMS patents claiming these compounds. PS433540 is a compound from the DARA program. Pharmacopeia will pay BMS milestone payments upon the achievement of successive clinical and regulatory events in the United States and certain other jurisdictions, and royalties on sales of products, if any, resulting from the DARA program.
Under the terms of the agreement, in lieu of an up-front cash payment, Pharmacopeia is providing BMS a set of compound libraries, over a period of approximately three years following the execution of the agreement. In the event...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company Ligand Pharmaceuticals, Inc.
Additional information available to subscribers only: